Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
G-202 in PSMA Positive Recurrent or Progressive Glioblastoma
NCT02876003Phase 2Withdrawn
- Sponsor
- Inspyr Therapeutics
- Start
- Sep 2016
- Primary completion
- Oct 2019
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
A Phase 2 trial of mipsagargin in glioblastoma (GBM), sponsored by Inspyr Therapeutics. Planned start Sep 2016; status: withdrawn.
02
Drugs
mipsagargin
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT02876003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02876003.